PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients

Alfonso Sánchez-Muñoz, R. Dueñas-García, A. Jaén-Morago, E. Carrasco, I. Chacón, A. M. García-Tapiador, A. L. Ortega-Granados, E. Martínez-Ortega, N. Ribelles, M. Fernández-Navarro, C. de la Torre-Cabrera, B. Dueñas, A. I. Rueda, J. Martínez, C. Ramírez Tortosa, M. D. Martín-Salvago, P. Sánchez-Rovira, Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients. American Journal of Clinical Oncology. ,vol. 33, pp. 432- 437 ,(2010) , 10.1097/COC.0B013E3181B4EFF9

Shanu Modi, Violante E. Currie, Andrew D. Seidman, Ariadne M. Bach, Katherine S. Panageas, Maria Theodoulou, Mark M. Moasser, Gabriella M. D'Andrea, Diana E. Lake, Jennifer Choi, Larry Norton, Clifford A. Hudis, A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical Breast Cancer. ,vol. 6, pp. 55- 60 ,(2005) , 10.3816/CBC.2005.N.009

Natalie Galanina, Veerle Bossuyt, Lyndsay N. Harris, Molecular Predictors of Response to Therapy for Breast Cancer The Cancer Journal. ,vol. 17, pp. 96- 103 ,(2011) , 10.1097/PPO.0B013E318212DEE3

Yufeng Liu, David Neil Hayes, Andrew Nobel, J. S Marron, Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data Journal of the American Statistical Association. ,vol. 103, pp. 1281- 1293 ,(2008) , 10.1198/016214508000000454

Gary K Geiss, Roger E Bumgarner, Brian Birditt, Timothy Dahl, Naeem Dowidar, Dwayne L Dunaway, H Perry Fell, Sean Ferree, Renee D George, Tammy Grogan, Jeffrey J James, Malini Maysuria, Jeffrey D Mitton, Paola Oliveri, Jennifer L Osborn, Tao Peng, Amber L Ratcliffe, Philippa J Webster, Eric H Davidson, Leroy Hood, Krassen Dimitrov, Direct multiplexed measurement of gene expression with color-coded probe pairs. Nature Biotechnology. ,vol. 26, pp. 317- 325 ,(2008) , 10.1038/NBT1385

Lisa A. Carey, Through a Glass Darkly: Advances in Understanding Breast Cancer Biology, 2000–2010 Clinical Breast Cancer. ,vol. 10, pp. 188- 195 ,(2010) , 10.3816/CBC.2010.N.026

M Gnant, M Filipits, B Mlineritsch, P Dubsky, R Jakesz, W Kwasny, F Fitzal, M Rudas, M Knauer, C Singer, R Greil, S Ferree, J Storhoff, JW Cowens, C Schaper, S Liu, T Nielsen, ABCSG, None, Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study Cancer Research. ,vol. 72, ,(2012) , 10.1158/0008-5472.SABCS12-P2-10-02

Charles M. Perou, Therese Sørlie, Michael B. Eisen, Matt van de Rijn, Stefanie S. Jeffrey, Christian A. Rees, Jonathan R. Pollack, Douglas T. Ross, Hilde Johnsen, Lars A. Akslen, Øystein Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley X. Zhu, Per E. Lønning, Anne-Lise Børresen-Dale, Patrick O. Brown, David Botstein, Molecular portraits of human breast tumours Nature. ,vol. 406, pp. 747- 752 ,(2000) , 10.1038/35021093

Catherine Van Poznak, Lee Tan, Katherine S. Panageas, Crispinita D. Arroyo, Clifford Hudis, Larry Norton, Andrew D. Seidman, Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 20, pp. 2319- 2326 ,(2002) , 10.1200/JCO.2002.08.125

Dorte L. Nielsen, Karsten D. Bjerre, Erik H. Jakobsen, Søren Cold, Lars Stenbygaard, Peter G. Sørensen, Claus Kamby, Susanne Møller, Charlotte L.T. Jørgensen, Michael Andersson, Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group Journal of Clinical Oncology. ,vol. 29, pp. 4748- 4754 ,(2011) , 10.1200/JCO.2010.33.9507